Every pharmaceutical organization we speak with wants to use AI. Anomaly detection. Predictive quality. AI-accelerated validation. GenAI agents for deviation support and SOP guidance. Almost none of them have the data foundation required to do any of this at scale in a GxP-compliant way.
This is not a technology problem. The AI models exist. The regulatory guidance, FDA's 2025 AI Draft Guidance, Annex 22 from EMA, the 2026 CSA Guidance, is increasingly clear. The problem is the data layer underneath the AI. And that layer has three structural gaps that most organizations have not yet addressed.
| AI in pharma is only as good as the data underneath it. And the data underneath it, in most pharmaceutical organizations, does not meet the ALCOA+ standard that both FDA compliance and GxP AI deployment require. |
The three data gaps that block AI readiness
Gap 1: Uncontrolled spreadsheets
Spreadsheets are used to support critical GxP decisions at virtually every pharmaceutical organization. But without controls, spreadsheet data has no audit trail, no access restrictions, and no input validation. FDA's 2025 AI Draft Guidance requires that training data for GxP AI models be accurate, complete, and traceable. Uncontrolled spreadsheet data meets none of these criteria.
Gap 2: Paper forms and records
Paper remains the default data capture mechanism for a significant fraction of GxP activities. Paper data cannot be used in an AI system without transcription, a process that introduces errors and breaks the chain of custody. More fundamentally, paper data cannot support real-time anomaly detection or predictive quality models. The data simply does not exist in a form AI can access.
Gap 3: Uncontrolled lab instrument data
Lab instruments generate raw data files continuously. In most pharmaceutical labs, these files sit in uncontrolled network folders accessible to all lab personnel, with no version management and no audit trail. FDA's 2018 Data Integrity guidance requires original raw data to be retained in its original form. For most organizations, this requirement is not fully met for instrument output files.
| WHY 2026 IS THE INFLECTION POINT |
|---|
| FY2024 saw the highest FDA warning letter volume in five years, with data integrity as the leading citation, up 11% from FY2023, with FY2025 pacing higher still. The 2025 FDA AI Draft Guidance creates new data quality requirements for GxP AI applications. The 2026 CSA Guidance rewards organizations with mature digital control environments. All three pressures are converging simultaneously. |
How CIMCON solves all three gaps
CIMCON has spent 30 years building the domain expertise and software products to address exactly these data integrity challenges in regulated environments. Three products map directly to the three gaps, and they work as a portfolio, each independently valuable, and together providing the complete data integrity foundation that GxP AI readiness requires.
| eInfotree Excel Desktop , Spreadsheet Compliance part11solutions.com/einfotree-excel-module-2/ |
|---|
Part 11 controls overlaid on existing Excel spreadsheets, no migration, no disruption, full ALCOA+ compliance.
|
| CIMCON TransForm , Paper Form Digitization part11solutions.com/digitizing-forms/ |
|---|
Convert paper GxP forms to electronic, Part 11-compliant digital forms, without redesigning them from scratch.
|
| CIMCON LabMonitor , Lab Instrument Data Control part11solutions.com/lab-management/ |
|---|
Continuous automatic monitoring of lab instrument folders, turning uncontrolled raw data files into ALCOA+-compliant, AI-ready records.
|
The three products address each gap independently, and they compound when deployed together. Controlled spreadsheet data, digitized form records, and monitored instrument files together create a data environment where every GxP-relevant data point is attributable, contemporaneous, original, and accurate. That environment supports both current compliance requirements and the AI-enabled quality applications that deliver the most value in pharmaceutical operations.
The remediation path and the AI payoff
The three gaps do not need to be addressed sequentially. Each independently produces compliance and AI returns. But there is a natural sequence that minimizes disruption while maximizing near-term impact.
- Start with eInfotree Excel Desktop: fastest deployment, no migration risk, immediate compliance improvement, and the XLValidator audit trail review capability unlocks AI anomaly detection from day one.
- Add TransForm for paper-dependent processes: structured database records replace unstructured paper, immediately expanding the data available for quality trending and AI analysis.
- Deploy LabMonitor for lab instrument data: completes the data integrity picture by bringing the most granular, highest-fidelity quality data in the organization under control and into the AI-accessible data environment.
| Organizations that build this foundation get compliance improvements immediately and AI readiness as a compounding benefit. The investment is not two separate programs, it is one data infrastructure that pays both dividends simultaneously. |
The bottom line
AI readiness in pharmaceutical operations is not primarily a technology question. The models exist, the guidance exists, and the use cases are clear. The question is whether the data layer meets the standard required for GxP AI deployment.
For most organizations, the honest answer today is no, but the path is well-defined. CIMCON's three products address the three structural gaps that stand between most pharmaceutical organizations and genuine AI readiness, with 30 years of regulatory expertise embedded in every control, every audit trail, and every validation package they ship.